sublayer

Board


Professor Gordon McVie – Non-Executive Chairman

Professor Gordon McVie is the international authority on the research and treatment of cancer. He is a Senior Consultant at the European Institute of Oncology, Visiting Professor at Glasgow University and Honorary Consultant in Medical Oncology at the Welsh Cancer Institute.


Mike von Bertele CB OBE – Non-Executive Director

Mike Von Bertele CV OBE is the International Director of Save the Children, working alongside the Department for International Development to combat Ebola in West Africa. He was the former Director General of the Army Medical Services. Mike was appointed OBE in 1994, Honorary Surgeon to Her Majesty The Queen in 2008 and CB in 2012.


Professor Sir Chris Evans OBE – Non-Executive Director

Professor Sir Chris Evans has a proven track record of establishing high-quality science companies, 20 of which have been taken public. He is widely regarded as Europe’s leading biotechnology entrepreneur and was appointed OBE in 1995 and Knighted in the New Year’s Honours List in 2001.


Mike Moran MBE - Chief Executive Officer

Mike Moran MBE is a founder of the company and has 30 years of experience in strategic leadership, planning and programme delivery. He has held various executive positions in defence and healthcare in the UK and abroad and is the Former Chairman of the Chamber of Commerce & Learning & Skills Council in Hereford and Worcestershire.


Professor Karol Sikora – Chief Medical Advisor

Professor Karol Sikora is a founder of the company and has more than forty years of experience as an oncologist treating patients worldwide. He is the Former Chief of the World Health Organisation’s Cancer Programme and is the founding team member and Clinical Director of Cancer Partners UK.


Paul Tuson - Chief Financial Officer

With over 20 years’ experience of finance roles predominantly with “TMT” companies, Paul Tuson has been group finance director or chief financial officer with four AIM-liste UK plcs. He has led successful flotations, secondary fundraisings and successful venture capital exits.